Rare Cancers & Finding a Specialist

Being told you have a rare cancer changes the practical problem you are solving. With a common cancer, the challenge is usually choosing among established options. With a rare one, the first challenge is often making sure the diagnosis is right. The second is finding someone who has treated more than one or two cases. Neither happens automatically.

The National Cancer Institute defines a rare cancer as one that affects fewer than 40,000 people per year in the United States. It also notes that rare cancers together account for a little over a quarter of all cancers. Childhood cancer is uncommon by nature, so all pediatric cancers fall into this category. Rare, in other words, is not rare in total. It is simply fragmented.

NCI describes the difficulties bluntly. Patients face long delays in diagnosis. They have trouble finding a knowledgeable specialist. Doctors may disagree about the best approach. And people often have to travel to get care. Physicians may not have been trained on a particular rare tumor. They may struggle to find an expert to consult, or to give the patient reliable information about prognosis. Researchers have their own problems. Basic information is missing, laboratory models are few, tumor samples are scarce, and there are too few patients to run conventional studies.

That last problem cascades into everything else. Fewer patients means less evidence. Less evidence means fewer standard protocols. And that means more variation in what you are offered, depending on where you walk in.

For a rare cancer, the diagnosis itself is the highest-stakes decision in the process. Everything after it follows from what the tumor is called. That includes surgery, drugs, radiation and trial eligibility.

Rare tumors are exactly the ones a general pathology service may see only occasionally. In some rare tumor types, specialist review at a referral center meaningfully changes diagnoses. Sarcomas are a clear example. This is not a criticism of anyone. It is a volume problem.

Ask directly for a second opinion on the pathology. Ask for it from a center that specializes in your tumor type. This is a routine request, not an insult. It is usually done by sending the existing slides and blocks, so no procedure is repeated. Ask specifically whether specialized testing is warranted. That means immunohistochemistry (a stain that shows which proteins a cell is making), and molecular or genomic testing. For several rare tumors, that testing defines the diagnosis rather than merely supporting it.

Do this before treatment starts if at all possible. Also request the full pathology report. Make sure you understand how the tumor was staged. Cancer staging explains what those categories mean and why they drive treatment decisions.

NCI-Designated Cancer Centers. The NCI Cancer Centers Program was set up under the National Cancer Act of 1971. It recognizes institutions that meet rigorous standards for cancer research. There are three designations: Basic Laboratory Cancer Centers, Clinical Cancer Centers, and Comprehensive Cancer Centers. The last is recognized for added breadth, and for research that bridges laboratory, clinical and population science. NCI keeps a "Find an NCI-Designated Cancer Center" directory on cancer.gov. Designation reflects research strength. So it is a strong starting filter, not a guarantee that a given center handles your specific tumor. You still have to ask.

Disease-specific tumor boards. Many centers run a board where pathologists, surgeons, radiologists and oncologists review a case together. Some run boards devoted to a single rare disease group, or to molecular findings. Ask whether your case can be presented at one. Then ask what the board concluded. You can request this even if you are being treated elsewhere.

Patient advocacy organizations. For most rare cancers, a disease-specific patient organization exists. These groups often keep the most current informal list of which clinicians actually see the disease. They are often faster than any official directory.

Registries and natural history studies. Rare cancers are scattered, so pooling data is how knowledge builds up. NCI runs the My Pediatric and Adult Rare Tumor network, MyPART, which includes a natural history study. Disease-specific registries exist for many individual rare tumors. Signing up is usually low-burden. It is one of the few ways to help the next patient.

For common cancers, a clinical trial is often a way to try something beyond an established standard. For many rare cancers there is no well-established standard. So a trial may be the option with the most evidence behind it, rather than a last resort.

Trial designs have also adapted. Basket trials enroll patients by a shared molecular alteration across different tumor types, rather than by tumor site. That is often how someone with a rare cancer becomes eligible for a drug developed for something else. This is one of the main reasons to push for molecular testing early. See what clinical trials are for how phases and eligibility work. Read that page before assuming a trial means a placebo.

• Ask for expert pathology review at a center that specializes in your tumor type, before treatment if possible.
• Ask whether molecular or genomic testing is indicated. Get the report itself, not just a summary.
• Get complete copies of everything: pathology, imaging on disc, operative notes. You will send them repeatedly.
• Search the NCI directory for designated centers. Then call and ask how many cases of your specific tumor they see per year.
• Contact the patient organization for your disease and ask who they see named most often.
• Ask for your case to go to a disease-specific or molecular tumor board.
• Ask about registries and natural history studies, including MyPART.
• Bring questions to ask before treatment begins to each consultation.
• If the cancer has spread, read metastatic cancer so you can follow what is being proposed.

All of this takes energy that you may not have. It usually falls to the patient or a family member, because no system assembles it for you. Travel or time off work may make some of it impossible. If so, say that out loud to your team. Remote pathology review and telehealth second opinions are often available, and they are far less demanding than they sound. What you are buying with this effort is not certainty. It is the confidence that the diagnosis is correct, and that someone with real experience of your specific disease has looked at your case.

• National Cancer Institute — About Rare Cancers (MyPART)
• National Cancer Institute — Pathology Reports Fact Sheet
• National Cancer Institute — Finding Cancer Care
• National Cancer Institute — Participate in MyPART